Changes in illicit drug use and markets with the COVID-19 pandemic and associated restrictions: findings from the Ecstasy and Related Drugs Reporting System, 2016–20

Title
Changes in illicit drug use and markets with the COVID-19 pandemic and associated restrictions: findings from the Ecstasy and Related Drugs Reporting System, 2016–20
Publication Date
2022-01
Author(s)
Price, Olivia
Man, Nicola
Bruno, Raimondo
Dietze, Paul
Salom, Caroline
Lenton, Simon
Grigg, Jodie
Gibbs, Daisy
Wilson, Tanya
Degenhardt, Louisa
Chan, Roanna
Thomas, Natalie
( author )
OrcID: https://orcid.org/0000-0002-3714-7626
Email: nthoma23@une.edu.au
UNE Id une-id:nthoma23
Peacock, Amy
Type of document
Journal Article
Language
en
Entity Type
Publication
Publisher
Wiley-Blackwell Publishing Ltd
Place of publication
United Kingdom
DOI
10.1111/add.15620
UNE publication id
une:1959.11/62430
Abstract

Aims To describe (i) self-reported changes in drug use and (ii) trends in price, perceived availability, and perceived purity of illicit drugs, among people who regularly use ecstasy/ 3,4-methylenedioxymethamphetamine (MDMA) and other illicit stimulants in Australia following COVID-19 and associated restrictions. Design Annual interviews with cross-sectional sentinel samples conducted face-to-face in 2016–19 and via video conferencing or telephone in 2020. Data were collected via an interviewer-administered structured questionnaire Setting Australian capital cities. Participants Australians aged 16 years or older who used ecstasy/MDMA and other illicit stimulants on a monthly or more frequent basis and resided in a capital city, recruited via social media and word-of-mouth (n ~ 800 each year). Measurements Key outcome measures were self-reported illicit drug market indicators (price, purity and availability) and, in 2020 only, perceived change in drug use (including alcohol and tobacco) since March 2020 and reasons for this change. Findings For most drugs, participants reported either no change or a reduction in their use since COVID-19 restrictions were introduced. Ecstasy/MDMA was the drug most frequently cited as reduced in use (n = 552, 70% of those reporting recent use), mainly due to reduced opportunities for socialization. While market indicators were largely stable across most drugs, the odds of perceiving MDMA capsules as ‘high’ in purity decreased compared with 2016–19 [adjusted odds ratio (aOR) = 0.72, 95% confidence interval (CI) = 0.53–0.99], as did perceiving them as ‘easy’ to obtain (aOR = 0.42, CI = 0.26–0.67). The odds of perceiving cocaine and methamphetamine crystal as ‘easy’ to obtain also decreased (aOR = 0.67, CI = 0.46–0.96 and aOR = 0.12, CI = 0.04–0.41, respectively). Conclusions After COVID-19-related restrictions were introduced in Australia, use of ecstasy/MDMA, related stimulants and other licit and illicit drugs mainly appeared to remain stable or decrease, primarily due to impediments to socialization.

Link
Citation
Addiction, 117(1), p. 182-194
ISSN
1469-2856
0965-2140
Start page
182
End page
194

Files:

NameSizeformatDescriptionLink
closedpublished/ChangesPrice2021JournalArticle.pdf 4669.65 KB application/pdf Published Version View document